IB NEURO

by Imaging Biometrics  · Based in United States → — Advanced AI-powered neuroimaging analysis for brain tumors.
Neurosurgery Oncology Radiology
Website
Claim this tool
Is this the maker? Claim the company →

Contact for pricing
Regulatory Status Disclosed

Overview

IB Neuro is an exclusive MRI perfusion platform developed by Imaging Biometrics that revolutionizes brain tumor imaging. It generates quantitative relative cerebral blood volume (rCBV) maps, providing critical insights into tumor biology and vasculature. This cutting-edge technology, backed by over 30 years of pioneering development, excels in differentiating tumor types, predicting tumor grades, and distinguishing post-treatment effects from tumor recurrence.

The platform processes both MRI dynamic susceptibility contrast (DSC) and CT perfusion datasets, automatically generating standardized sRCBV maps that quantify tumor vascularity with clarity and consistency. IB Neuro incorporates a proven contrast leakage algorithm and patented standardization technology, ensuring broad compatibility and consistency across all MRI platforms. It has been shown to be reliable using 50% less gadolinium-based contrast agent for both 1.5T and 3T MRI.

IB Neuro’s quantitative output has undergone independent validation with tissue samples, demonstrating superior accuracy and repeatability over other perfusion methods. It is trusted by leading brain tumor centers and utilized in national multi-center clinical trials for its reliable analysis capabilities.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Generates quantitative relative cerebral blood volume (rCBV) maps
  • Differentiates tumor types and predicts tumor grades
  • Distinguishes post-treatment effects from tumor recurrence
  • Processes MRI dynamic susceptibility contrast (DSC) and CT perfusion datasets
  • Incorporates a proven contrast leakage algorithm
  • Utilizes patented standardization technology for consistent results across MRI platforms
  • Proven reliable with 50% less gadolinium-based contrast agent
  • Automates generation of standardized sRCBV maps
  • Results in high inter-reader agreement and confidence
  • Aids in assessing residual enhancing tumor after surgery

Use Cases

  • Assessment of brain tumors before, during, and after therapy
  • Differentiating tumor regrowth from normal treatment effects
  • Guiding therapeutic and surgical management of glioma patients
  • Evaluating subtle enhancement in complex neuroimaging cases
  • Supporting multi-center clinical trials and research
  • Streamlining decision-making in neuro-oncology care

What Physicians Need to Know

Brain MRI/CT Analysis
IB Neuro is an exclusive MRI perfusion platform that generates quantitative relative cerebral blood volume (rCBV) maps, validated for accuracy and repeatability. It processes CT perfusion datasets and utilizes a proprietary leakage correction algorithm to differentiate tumor types, predict tumor grades, and distinguish post-treatment effects from tumor recurrence. The suite also includes IB Delta T1 Maps for delineating true contrast enhancement and IB Diffusion for analyzing MR diffusion-weighted images to detect microscopic changes in water mobility.
Neurodegenerative Disease Screening
The broader Imaging Biometrics suite includes IB ASL, a software solution for non-invasive, quantitative measurement of cerebral blood flow (CBF) using MRI, which is ideal for assessing dementia and neurodegenerative disease monitoring.
Mobile Notification System
The IB Nimble mobile app provides HIPAA-compliant collaboration, real-time perfusion analytics, and streamlined decision-making workflows, enabling access to critical data and potentially notifications on mobile devices.
Physician Tip

Leverage IB Neuro's quantitative rCBV maps and advanced leakage correction for precise brain tumor characterization, including differentiation of tumor recurrence from treatment effects. Utilize IB Delta T1 Maps for accurate assessment of true contrast enhancement and IB Diffusion for early detection of microscopic tissue changes. Integrate these tools to guide biopsy, surgical resection, and monitor treatment response in neuro-oncology cases, enhancing diagnostic confidence and inter-reader agreement. Consider IB ASL for non-contrast cerebral blood flow assessment in stroke and neurodegenerative disease monitoring.

IB Neuro and its suite are designed for seamless integration with existing PACS and clinical routines, ensuring efficient processing. The platform is compatible with FDA-cleared systems like the aycan workstation and supports data analysis across various MRI vendor platforms, providing broad compatibility and consistency.

Details

Category Neurology AI, Oncology AI, Radiology & Imaging AI
Pricing Contact for pricing
DeploymentSoftware application (historically available as an OsiriX plug-in, likely integrated into PACS/workstations)
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

IB Neuro, Version 1.0, received FDA 510(k) clearance (K080762) on May 15, 2008, as an MR perfusion software package for generating and displaying perfusion parameter color maps.
Integrations
EHR Not specified
Specialties Neurosurgery, Oncology, Radiology

What the Web Says

IB Neuro, developed by Imaging Biometrics (IB), is a software solution primarily used in neuro-oncology for advanced imaging and MRI technology. It aids in diagnosing and grading brain tumors and evaluating therapy effectiveness. The software utilizes dynamic susceptibility contrast MRI (DSC-MRI) to generate quantitative relative cerebral blood volume (rCBV) maps and Fractional Tumor Burden (FTB) maps, which are crucial for distinguishing active tumor progression from treatment-related effects. Physicians and clinical partners have endorsed the importance of DSC-MRI for accurate brain tumor assessment, a core capability of IB Neuro.

Overall: Positive

Strengths

  • Accurate in distinguishing between tumor and normal brain tissue.
  • Provides quantitative rCBV and FTB maps for precise tumor assessment.
  • Useful for guiding biopsies and surgical plans due to fine-grained, voxel-level resolution.
  • Automated and standardized for consistent results across scanners and patients.
  • Integrates with existing clinical workflows.
  • Endorsed by expert panels for its utility in neuro-oncology.

Limitations

  • No specific cons for IB Neuro were found in the provided search results.
  • General challenges in neurology residency include a high burden of emergencies and long hours.
  • Some review platforms (G2, Capterra) have general negative feedback regarding their own user experience, customer service, and incentivized review processes, which might affect the perception of reviews hosted on them.

Based on reviews from: Imaging Biometrics 2026 Company Profile: Valuation, Investors, Acquisition | PitchBook, AJR Review Endorses Advanced Imaging Techniques, Validating Imaging Biometrics' Tools for Brain Tumor Assessment | Applied Radiology, Analysis Of Perfusion And Diffusion-Based Exams. | Imaging Biometrics, IB Resources - Imaging Biometrics, Can someone honestly tell me how neuro residency is. The good, bad, ugly : r/neurology, G2 Reviews | Read Customer Service Reviews of www.g2.com - Trustpilot Reviews, Capterra Reviews - 10 Customers Rate 2.0/5 (2026) | SmartCustomer, Neuro Software Pricing, Alternatives & More 2026 - Capterra, Interventional neurology life : r/Residency - Reddit, Read Customer Service Reviews of www.capterra.com | 2 of 48 - Trustpilot

Last updated: 2026-07-20

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate IB NEURO

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

FirstWord PHARMA
IB Neuro Commercialisation Plan - ASCO 2026 Phase II Results and Strategic Revenue Pathway
Imaging Biometrics Limited announced the results of the EAF151 Phase II clinical trial at the ASCO 2026 Annual Meeting, outlining plans to drive revenue growth from its IB Neuro platform. The study validated IB Neuro's automated imaging biomarker for predicting overall survival in recurrent glioblastoma, offering an early and objective assessment of treatment response.
2026-06
TipRanks
Imaging Biometrics Targets Revenue Growth After ASCO Validation of IB Neuro
Imaging Biometrics reported new Phase II clinical data from the EAF151 trial, presented at ASCO 2026, demonstrating that its IB Neuro platform can generate automated standardized relative cerebral blood volume metrics that strongly correlate with overall survival in patients with recurrent glioblastoma.
2026-06
Pluang
Trial validates Imaging Biometrics' brain cancer tool predicting survival in glioblastoma patients
Imaging Biometrics' IB Neuro platform has been validated by a major US clinical trial (EAF151 phase II) as an effective tool to predict survival in patients with recurrent glioblastoma, a severe brain cancer. The trial showed that IB Neuro's automated cerebral blood volume measurement strongly correlates with overall survival, outperforming manual methods.
2026-06
Investing.com
Imaging Biometrics reports phase II trial results for brain tumor software
Imaging Biometrics Limited announced results from the EAF151 Phase II clinical trial, presented at the American Society of Clinical Oncology Annual Meeting, which evaluated whether cerebral blood volume measurements derived from MRI scans using IB Neuro software could serve as an early biomarker of response to bevacizumab in recurrent glioblastoma patients.
2026-05
Imaging Biometrics
Reduced Gadolinium Approach Validated with IB Neuro on 1.5T MR Scanners
Imaging Biometrics, LLC announced the results of a study validating IB Neuro's processing of reduced-dose gadolinium-based contrast agent (GBCA) perfusion studies on 1.5T scanners. This makes IB Neuro the only platform proven to provide accurate perfusion maps under low-dose conditions at both 1.5T and 3T MR scanners.
2023-09
AuntMinnie
Imaging Biometrics touts IB Neuro study
Imaging Biometrics highlighted a study featuring its IB Neuro software for assessing brain tumors, where researchers identified distinct imaging patterns that matched key genetic and molecular features of invasive tumor margins.
2023-10
Imaging Biometrics
Imaging Biometrics Expands Distribution
Imaging Biometrics (IB) renewed its distribution agreement with GE HealthCare, allowing GE HealthCare to directly sell IB Neuro and IB Delta T1 platforms to both existing and new customers.
2024-11
Imaging Technology News
IB Neuro Earns Recognition as National Standard for Use in High-grade Brain Tumors
Imaging Biometrics announced that its MRI DSC perfusion technology, first made commercially available in IB Neuro, earned recognition as the national standard for use in high-grade brain tumors, following findings published in Neuro Oncology.
2020-06

Videos

Product demos, reviews, and walkthroughs for IB NEURO.

View all on YouTube

Frequently Asked Questions

IB NEURO is an MRI perfusion platform that generates quantitative relative cerebral blood volume (rCBV) maps, providing critical insights into tumor biology and vasculature. It integrates by processing DSC-MRI and CT perfusion datasets to aid in differentiating tumor types, predicting tumor grade, and distinguishing post-treatment effects from tumor recurrence, streamlining decision-making in neuro-oncology care.
As an AI-powered medical device, IB NEURO falls under FDA regulations, requiring appropriate premarket pathways and postmarket surveillance. Healthcare providers must ensure HIPAA compliance for patient data, conduct local validation of the system within their specific clinical context, and adhere to transparency regulations regarding AI use and patient consent.
While traditional diagnostic methods for neuroimaging exist, they can be time-consuming and prone to human error in detecting subtle changes. IB NEURO offers automated, quantitative analysis of MRI dynamic susceptibility contrast (DSC) studies, with independent validation showing it exceeds the accuracy and repeatability of other perfusion methods, even with reduced contrast agent.
Pricing models for healthcare AI solutions can vary, including fixed cost, consumption-based, customized solutions, or hybrid models combining a base fee with variable components. Factors influencing cost include the scope and complexity of the AI project, data quality and processing requirements, and the level of customization and ongoing support needed.
Limitations of AI in neurological diagnostics include the 'black box' nature of some algorithms, potential biases from training data, and the need for robust external validation across diverse populations. While AI can assist, the physician's role remains crucial for interpreting data, understanding the context, and making final treatment decisions, emphasizing the need for transparency and continuous research.
IB NEURO's quantitative output has undergone independent validation with tissue samples, demonstrating superior accuracy and repeatability over other perfusion methods. It incorporates a proven contrast leakage algorithm and patented standardization technology, and has been used in national multi-center clinical trials, ensuring reliable analysis across different MRI vendor platforms and field strengths.
While specific training details for IB NEURO are not fully outlined, effective AI governance in hospitals requires documented decision-making processes that include input from all stakeholders, and organizations must provide training and standard operating procedures for AI tools. Vendors are generally expected to treat integration, training, and ongoing support as core components of their offerings.

Related Tools

DETECT-ME/CFS project
ME/CFS Research Foundation (Sponsor: Federal Ministry of Health (BMG))
Clinical Decision Support & Reference
The DETECT-ME/CFS project is developing an AI-supported clinical decision support system to improve the rapid and reliable diagnosis of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Neurotrack
Neurotrack
Clinical Decision Support & Reference
Neurotrack is a cognitive care enablement platform that provides clinically validated, FDA class II device assessments and care planning support to identify and manage cognitive decline and dementia earlier and with greater accuracy.
LesionQuant
CorTechs Labs
Neurology AI
LesionQuant, an FDA-approved AI product by CorTechs Labs, is particularly useful for patients with multiple sclerosis. It provides brain structure data and quantifies the number, size, and location of lesions, comparing them to prior studies.
ExcelsiusGPS
Globus Medical
Neurology AI
ExcelsiusGPS™ is the first and only robotic navigation platform on the market that offers a comprehensive approach to spine and cranial procedures, from start to finish. The system enables repeatable and accurate trajectory alignment and navigation for placing screws, interbody implants, and cranial instruments.
Paid
Onera SleepMap
Onera B.V.
Neurology AI
Onera SleepMap is an AI-powered sleep analysis software that processes polysomnography data, part of Onera Health's innovative patch-based system for at-home and in-lab sleep studies. The system aims to make clinical-grade sleep diagnostics more accessible and user-friendly, providing comprehensive data comparable to traditional in-lab PSG.
Per-test pricing
JLK-NCCT
JLK-NCCT
Clinical Decision Support & Reference
JLK-NCCT is an AI software designed to assist in the analysis of non-contrast CT brain scans for the detection of acute ischemic stroke.

See all Neurology AI tools →

Suggest an Edit → | Last Verified: 2026-04-19 | First Added: 2026-04-19
AI Tool Finder
AI-powered search. Results may not be comprehensive.